US Wrap: JP Morgan interrupts US equity whitewash with China note

In a day dominated by exposure to US equity, JP Morgan took investors in a different direction by offering a note linked to Chinese blue chip companies. The product is a two-year autocallable note linked to the iShares FTSE/Xinhua China 25 Index fund, which tracks 25 of the largest and most liquid Chinese stocks trading on the Hong Kong Stock Exchange. If the index is at or above its level at strike after one year, then the structure kicks out with a return of 20-22%. Should the product continue, subsequent observation dates are six months apart and will pay respective coupons of 30-33%, and 40-44%. The structure incorporates a relatively narrow protection barrier of 10% on the index, beyond which principal is not protected at maturity.

The rest of the day's issuance focused on the S&P 500, alongside three US stocks in three reverse convertible notes from JP Morgan, including Caterpillar, Goldman Sachs for the second day in a row, and General Electric. Merrill Lynch launched an accelerated growth note linked to the Russell 2000 index, which incorporates small-cap US stocks. It opted to use the external paper of Swedish Export Credit to issue the product.

Issuer

Product type

Underlying

Pricing date

Maturity date

Swedish Export Credit

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here